Major Depressive Disorder
Major Depressive Disorder Market

Major Depressive Disorder (MDD) is one of the most prevalent psychiatric disorders and has been projected by the World Health Organization to be the leading cause of disease burden in high-income countries by 2032. It is characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions.


It is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation or agitation, sleep disturbances, or suicidal thoughts.


Major Depressive Disorder Epidemiology Segmentation


• 12 Months Major Depressive Disorder Prevalent Cases 

• Gender-specific Major Depressive Disorder Prevalent Cases

• Severity-specific Major Depressive Disorder Prevalent Cases 

• Relapsed/Refractory Major Depressive Disorder Cases


Major Depressive Disorder Epidemiological Insights


  • The total 12-month Major Depressive Disorder prevalent cases in the 7MM in the year 2020 were found to be 43,845,330.
  • The Major Depressive Disorder prevalent population in the United States was observed to be 21,711,068 cases, whereas 5,536,067 prevalent cases were found in France, 5,241,312 prevalent cases in Germany and 3,143,384 prevalent cases in Japan.
  • The Severity-specific Major Depressive Disorder incident cases in the United States were estimated to be 6,578,453 mild cases, whereas 8,619,294 cases were reported to be moderate and 6,513,320 severe cases of Major Depressive Disorder were found in the year 2020. 


Major Depressive Disorder Market Insight


The market size of Major Depressive Disorder in the United States was found to be USD 3,960.6 million in the year 2020.  


Major Depressive Disorder Market Drivers


• Introduction of a new pathway

• Increasing awareness on depression

• Increasing spending on branded drugs


Major Depressive Disorder Market Barriers 

• Challenges in diagnosis

• Economic burden

• Generic products


Major Depressive Disorder Emerging Drugs

• AXS-05

• Travivor

• SAGE-217

• VRAYLAR (Cariprazine)

• CTC-501

• LY03005

• MIN-202 (Seltorexant)

• REL-1017

• PRAX-114

• PDC-1421

• PH10

• AV-101

• CAPLYTA (Lumateperone), and several others


Major Depressive Disorder Key Players

  • Axsome Therapeutics
  • Fabre-Kramer Pharmaceuticals
  • SAGE Therapeutics
  • Allergan
  • Gedeon Richter
  • Chase Therapeutics
  • Luye Pharma
  • Janssen Pharmaceuticals
  • Minerva Neurosciences
  • Relmada Therapeutics
  • Praxis Precision Medicines
  • BioLite Inc., and several others.